Antitussive effect of dihydroetorphine in mice

Eur J Pharmacol. 1994 Aug 1;260(2-3):257-9. doi: 10.1016/0014-2999(94)90347-6.

Abstract

The present study examined the opioid receptors involved in the antitussive effect of dihydroetorphine in mice. Dihydroetorphine suppressed coughs dose dependently at doses between 0.1-1 micrograms/kg i.p. Blockade of mu-opioid receptors by pretreatment with beta-funaltrexamine significantly reduced the antitussive effect of dihydroetorphine. Furthermore, the antitussive effect of dihydroetorphine was also antagonized by nor-binaltorphimine, a kappa-opioid receptor antagonist. However, pretreatment with naltrindole, a delta-opioid receptor antagonist, did not affect the antitussive effect of dihydroetorphine. These results indicate that the antitussive effect of dihydroetorphine is mediated by the activation of mu-opioid receptors and of kappa-opioid receptors, but not delta-opioid receptors.

MeSH terms

  • Alkylating Agents / pharmacology
  • Animals
  • Antitussive Agents / administration & dosage
  • Antitussive Agents / pharmacology*
  • Antitussive Agents / therapeutic use
  • Cough / drug therapy*
  • Dose-Response Relationship, Drug
  • Etorphine / administration & dosage
  • Etorphine / analogs & derivatives*
  • Etorphine / pharmacology
  • Etorphine / therapeutic use
  • Injections, Intraperitoneal
  • Male
  • Mice
  • Naltrexone / analogs & derivatives
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology
  • Receptors, Opioid / drug effects*
  • Receptors, Opioid / metabolism
  • Receptors, Opioid, delta / drug effects
  • Receptors, Opioid, delta / metabolism
  • Receptors, Opioid, kappa / drug effects
  • Receptors, Opioid, kappa / metabolism
  • Receptors, Opioid, mu / drug effects
  • Receptors, Opioid, mu / metabolism

Substances

  • Alkylating Agents
  • Antitussive Agents
  • Narcotic Antagonists
  • Receptors, Opioid
  • Receptors, Opioid, delta
  • Receptors, Opioid, kappa
  • Receptors, Opioid, mu
  • binaltorphimine
  • Etorphine
  • Naltrexone
  • beta-funaltrexamine
  • 18,19-dihydroetorphine